Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common non-traumatic cause of disability in young adults. Recent research shows that vascular disease risk factors (VDRFs) such as obesity, smoking, hyperlipidemia, hypertension, type II diabetes mellitus, and metabolic syndrome, can influence MS on its onset, disease activity, progression, and resultant disability. This review evaluates the current knowledge on the role of VDRFs on outcomes among people with MS (PwMS) and shows that while VDRF prevalence may or may not be higher among PwMS compared with the general population, its presence can influence MS in myriad ways. Management of VDRFs through early detection and treatment may be a promising approach to improving outcomes in PwMS.
Multiple sclerosis, smoking, obesity, dyslipidemia, hypertension, type II diabetes, metabolic syndrome
No funding was received in the publication of this article. Meena Kannan and Vijayshree Yadav have no relevant conflicts of interest to declare.
Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.
Vijayshree Yadav, Mail Code L226, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, US. E: email@example.com
This article is published under the Creative Commons Attribution Noncommercial License, which
permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.
Share this Article
Related Content In Multiple Sclerosis
Siponimod—A Selective Sphingosine-1-phosphate Modulator for Secondary Progressive Multiple Sclerosis
US Neurology. 2020;16(2):99–102 DOI: https://doi.org/10.17925/USN.2020.16.2.99
Multiple sclerosis (MS) is a chronic neuro-inflammatory condition estimated to affect over two million people worldwide. Several subtypes of MS have been described, and they are defined by their clinical phenotypes.1 The majority of patients initially exhibit relapsing remitting MS (RRMS), which is characterized by acute episodes of overt inflammation associated with abrupt clinical decline, most […]
Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
European Neurological Review. 2020;15(1):27-35 DOI: https://doi.org/10.17925/ENR.2020.15.1.27
Multiple sclerosis (MS) has traditionally been considered a primarily T-cell-mediated autoimmune disease of the central nervous system (CNS); this is based on data from animal models,1 the presence of activated T lymphocytes in MS plaques that outnumber B cells and T-cell subset alterations in blood,2 the association of MS with certain human leukocyte antigen (HLA) and a […]
Ozanimod in Multiple Sclerosis
European Neurological Review. 2019;14(2):73–9
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system affecting almost 3 million individuals worldwide.1–3 The precise pathogenesis of the disease is unknown, though migration of peripheral T and B lymphocytes into the central nervous system is considered to be one of the major pathophysiologic mechanisms.4–6 Sphingosine-1-phosphate (S1P) modulators, through induction of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!